Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lolke de Haan

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Infection and Immunity|February 22, 2003
Mutant Escherichia coli heat-labile toxin B subunit that separates toxoid-mediated signaling and immunomodulatory action from trafficking and delivery functionsSylvia A Fraser, Lolke de Haan, Arron R Hearn, et al.
Clinical & Translational Immunology|November 11, 2020
Use of human splenocytes in an innovative humanised mouse model for prediction of immunotherapy-induced cytokine release syndromeAlba Matas-Céspedes, Lee Brown, Krishnaa T Mahbubani, et al.
Regulatory Toxicology and Pharmacology : RTP|July 30, 2015
Nonclinical safety testing of biopharmaceuticals--Addressing current challenges of these novel and emerging therapiesFrank R Brennan, Andreas Baumann, Guenter Blaich, et al.
Archives of Toxicology|March 18, 2018
The future trajectory of adverse outcome pathways: a commentaryFiona Sewell, Nichola Gellatly, Maria Beaumont, et al.
Regulatory Toxicology and Pharmacology : RTP|November 22, 2011
The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primatesKathryn L Chapman, Laura Andrews, Jeffrey J Bajramovic, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 29, 2024
Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplantJenny Yeung, Aiyin Liao, Matthew Shaw, et al.
Molecular Cancer Therapeutics|March 17, 2018
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion ProteinMichael D Oberst, Catherine Augé, Chad Morris, et al.
Regulatory Toxicology and Pharmacology : RTP|January 2, 2023
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approachHsiao-Tzu Chien, Helen Prior, Laura Andrews, et al.
Regulatory Toxicology and Pharmacology : RTP|January 17, 2023
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remainHelen Prior, Laura Andrews, Annick Cauvin, et al.
Nature Reviews. Drug Discovery|March 29, 2013
Challenges and approaches for the development of safer immunomodulatory biologicsJean G Sathish, Swaminathan Sethu, Marie-Christine Bielsky, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Infection and Immunity|February 22, 2003
Mutant Escherichia coli heat-labile toxin B subunit that separates toxoid-mediated signaling and immunomodulatory action from trafficking and delivery functionsSylvia A Fraser, Lolke de Haan, Arron R Hearn, et al.
Clinical & Translational Immunology|November 11, 2020
Use of human splenocytes in an innovative humanised mouse model for prediction of immunotherapy-induced cytokine release syndromeAlba Matas-Céspedes, Lee Brown, Krishnaa T Mahbubani, et al.
Regulatory Toxicology and Pharmacology : RTP|July 30, 2015
Nonclinical safety testing of biopharmaceuticals--Addressing current challenges of these novel and emerging therapiesFrank R Brennan, Andreas Baumann, Guenter Blaich, et al.
Archives of Toxicology|March 18, 2018
The future trajectory of adverse outcome pathways: a commentaryFiona Sewell, Nichola Gellatly, Maria Beaumont, et al.
Regulatory Toxicology and Pharmacology : RTP|November 22, 2011
The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primatesKathryn L Chapman, Laura Andrews, Jeffrey J Bajramovic, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 29, 2024
Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplantJenny Yeung, Aiyin Liao, Matthew Shaw, et al.
Molecular Cancer Therapeutics|March 17, 2018
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion ProteinMichael D Oberst, Catherine Augé, Chad Morris, et al.
Regulatory Toxicology and Pharmacology : RTP|January 2, 2023
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approachHsiao-Tzu Chien, Helen Prior, Laura Andrews, et al.
Regulatory Toxicology and Pharmacology : RTP|January 17, 2023
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remainHelen Prior, Laura Andrews, Annick Cauvin, et al.
Nature Reviews. Drug Discovery|March 29, 2013
Challenges and approaches for the development of safer immunomodulatory biologicsJean G Sathish, Swaminathan Sethu, Marie-Christine Bielsky, et al.
Pageof 3